Evidence map›Paper›PMID 39167182›Full record

SynthesisAnnals of hematology2024

Prognostic significance of CRLF2 in patients with acute lymphoblastic leukemia: a meta-analysis and systematic review.

Zilu Meng, Hanxue Zheng, Yang Liu, Xiaojia Guo, Songlin Chu, Wen Zhou, Yanhong Li, Jun Bai, Liansheng Zhang, Lijuan Li

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Annals of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zilu MengDepartment of Hematology, The Second Hospital of Lanzhou University, Lanzhou University, No.82, Cuiyingmen, Chengguan District, Lanzhou, 730030, Gansu Province, China.
Hanxue ZhengDepartment of Hematology, The Second Hospital of Lanzhou University, Lanzhou University, No.82, Cuiyingmen, Chengguan District, Lanzhou, 730030, Gansu Province, China.
Yang LiuDepartment of Hematology, The Second Hospital of Lanzhou University, Lanzhou University, No.82, Cuiyingmen, Chengguan District, Lanzhou, 730030, Gansu Province, China.
Xiaojia GuoDepartment of Hematology, The Second Hospital of Lanzhou University, Lanzhou University, No.82, Cuiyingmen, Chengguan District, Lanzhou, 730030, Gansu Province, China.
Songlin ChuDepartment of Hematology, The Second Hospital of Lanzhou University, Lanzhou University, No.82, Cuiyingmen, Chengguan District, Lanzhou, 730030, Gansu Province, China.
Wen ZhouDepartment of Hematology, The Second Hospital of Lanzhou University, Lanzhou University, No.82, Cuiyingmen, Chengguan District, Lanzhou, 730030, Gansu Province, China.
Yanhong LiKey Laboratory of the Hematology of Gansu Province, The Second Hospital of Lanzhou University, Lanzhou University, Lanzhou, 730000, Gansu, China.
Jun BaiKey Laboratory of the Hematology of Gansu Province, The Second Hospital of Lanzhou University, Lanzhou University, Lanzhou, 730000, Gansu, China.
Liansheng ZhangDepartment of Hematology, The Second Hospital of Lanzhou University, Lanzhou University, No.82, Cuiyingmen, Chengguan District, Lanzhou, 730030, Gansu Province, China. zhanglsh@lzu.edu.cn.
Lijuan LiDepartment of Hematology, The Second Hospital of Lanzhou University, Lanzhou University, No.82, Cuiyingmen, Chengguan District, Lanzhou, 730030, Gansu Province, China. doctorjuan@sina.com.

Funding

Commissioned by the National Clinical Medical Research Center for Hematological Diseases 2021WWA01Construction of clinical medical research center of Gansu Science and Technology project 21JR7RA435Gansu Province science and technology project natural science foundation 21JR7RA394Supported by the National Natural Science Foundation of China 82360029
6 · The paper itself

Abstract

The association between cytokine receptor-like factor 2 (CRLF2) and clinical outcomes in acute lymphoblastic leukemia (ALL) has been a topic of ongoing debate, with divergent findings. This article intended to investigate the influence of CRLF2 alterations on ALL prognosis. Following the PRISMA 2020 guidelines, this meta-analysis was conducted. Hazard ratio (HR) values and confidence intervals (CIs) were the primary statistical measures used. Data heterogeneity was judged using the chi-square test and I

Indexed as

Biomarkers, TumorPrecursor Cell Lymphoblastic Leukemia-LymphomaReceptors, CytokineChildDisease-Free SurvivalHumansPrognosisSurvival RateBiomarkers, TumorCRLF2 protein, humanReceptors, CytokineAcute lymphoblastic leukemiaCytokine receptor-like factor 2Meta-analysisPrognosisSystematic review

Identifiers

PMID39167182

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.